A careful reassessment of anthracycline use in curable breast cancer
Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of...
Guardado en:
Autores principales: | Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aad7894979b94db08a790483d6338a18 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiac and skeletal muscle predictors of impaired cardiorespiratory fitness post-anthracycline chemotherapy for breast cancer
por: Amy A. Kirkham, et al.
Publicado: (2021) -
Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
por: Li-Yan Zhou, et al.
Publicado: (2015) -
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
por: Jason J Zoeller, et al.
Publicado: (2021) -
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
por: Craig Davison, et al.
Publicado: (2021) -
Genetic basis of anthracyclines cardiotoxicity: Literature review
por: M. Yu. Sinitsky, et al.
Publicado: (2021)